SINTX Technologies Reiterates Commercialization Focus and Strategic Direction.

SINTX Technologies, a ceramics innovator, has made significant progress with its SiNAPTIC acquisition and strategic transformation. The company has revamped its commercialization strategy to accelerate growth over the next 12-24 months. Chairman and CEO Eric Olson believes SINTX is poised to lead the next wave of innovation in medical technology.

SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, has made significant strides in its strategic reorientation and growth plans. The company, based in Salt Lake City, Utah, recently issued a business update following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2025 [1].

The update highlights meaningful progress from the company’s recent acquisition of SiNAPTIC Surgical, LLC, a significant strategic transformation, and a revitalized commercialization strategy aimed at accelerating growth over the next twelve to twenty-four months. Chairman and CEO Eric Olson stated, "SINTX is now positioned to lead the next wave of innovation in medical technology" [1].

The acquisition of SiNAPTIC has brought a proven team of MedTech innovators to SINTX, significantly enhancing its depth and commercial capabilities. Key additions include Bryan Scheer, M.D., as Chairman of the Clinical Advisory Board, Hugh Roberts as Managing Director of Business Development, Lisa Marie Del Re as Chief Commercial Officer, and Brian Hockett as Senior Vice President of Regulatory and Quality Affairs [1].

SINTX has also streamlined its operations by divesting non-core assets and terminating non-strategic operations. The company sold its Maryland-based subsidiary, Technology Assessment & Transfer, Inc. (TA&T), in February 2025, and officially shut down its armor ceramics facility in August 2024 [1].

Looking ahead, SINTX will continue to build on its scientific foundation and IP portfolio with meaningful and long-term performance impact. Recent advancements include multiple new patents related to composite implant design, additive manufacturing, and antimicrobial ceramics, as well as peer-reviewed publications validating the performance of silicon nitride in orthopedic and surgical applications [1].

Olson emphasized, "We are moving decisively toward commercialization. And as we do, we will provide the kind of transparency our shareholders expect" [1].

For more information, visit [www.sintx.com](http://www.sintx.com).

References:
[1] SINTX Technologies, Inc. (2025). Company Reinforces Commercialization Focus and Strategic Direction. Retrieved from [https://www.marketscreener.com/news/sintx-technologies-issues-business-update-following-strategic-realignment-leadership-expansion-and-ce7c51dedd81f325](https://www.marketscreener.com/news/sintx-technologies-issues-business-update-following-strategic-realignment-leadership-expansion-and-ce7c51dedd81f325)